Wayne J. G. Hellstrom MD, FACS
Professor of Urology and Chief of Andrology (Male Infertility and Sexual Dysfunction), Tulane University School of Medicine, New Orleans, LouisianaDr. Wayne Hellstrom is a board-certified Professor of Urology and Chief of Andrology at Tulane University School of Medicine. He received his MD from McGill Medical School in Montreal, followed by a residency there in general surgery. He completed a residency in urology at the University of California in San Francisco and an AUA scholar-funded fellowship in andrology at the University of California at Davis. Having instructed more than 30 fellows, visiting students, residents, and physicians, Dr. Hellstrom practices as a urologist at Tulane Medical Center, University Medical Center New Orleans, and the New Orleans Veterans Administration Medical Center, where he specializes in the diagnosis and treatment of sexual dysfunction, including Peyronie’s disease, surgical and vascular reconstruction, prosthetic surgery, male infertility (both surgical and medical therapies), BPH, and urethral stricture disease. A member of numerous professional societies, he is the former President of the Sexual Medicine Society of North America (SMSNA), the American Society of Andrology (ASA), and the International Society of Sexual Medicine (ISSM). The Associate Editor of Urology (Gold Journal) and an Editorial Board Member for the Journal of Urology, US Urology, and the Asian Journal of Andrology, as well as a reviewer for numerous journals, he has authored or coauthored over 100 book chapters and more than 550 manuscripts in peer-reviewed journals. The editor of several textbooks in the field of andrology, including Male Infertility and Sexual Dysfunction (1997), Handbook of Sexual Dysfunction (1999), Androgen Deficiency and Testosterone Replacement (2013), and Bioenvironmental Issues Affecting Men’s Reproductive and Sexual Health (2017), he has delivered numerous presentations locally, nationally, and internationally on various topics in male sexual dysfunction and male infertility.
Disclosures
Dr. Hellstrom reports financial interest/arrangements or affiliations with:- Acerus Pharma, Consultant or Advisor
- Boston Scientific– Consultant or Advisor
- Coloplast – Consultant or Advisor
- Endo – Consultant or Advisor, Investigator, Lecturer
- Gilead – Advisory Board Member
- Maximus – Advisory Board Member
- Promescent – Advisory Board Member
- Theralogix – Board Member, Officer, Trustee
Recent Contributions to PracticeUpdate:
- A Novel Collagenase Administration Protocol to Improve Penile Curvature in Peyronie's Disease
- AUA 2022: Penile Traction Therapy Improves Erectile Function, Penile Length After Prostatectomy
- Continuing Collagenase Clostridium Histolyticum Injections and Curvature Improvements in Peyronie's Disease
- Long-Term Surgical, Functional, and Patient-Reported Outcomes of a Modified Corporoplasty
- Safety and Efficacy of Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease
- Safety of Collagenase C. histolyticum for Peyronie Disease in Patients Using Antiplatelet or Anticoagulant Therapy
- How Cannabis Alters Sexual Experience
- Cost Effectiveness of Surgery, Collagenase Clostridium histolyticum, and Penile Traction Therapy in Men With Peyronie’s Disease
- Low Free Testosterone Is Associated With a Low Prostate Cancer Risk
- Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease